mRNA-Lipid Nanoparticle Strategy Utilizes Measles Immunity for Cancer Immunotherapy
A recent study has demonstrated a novel approach to cancer immunotherapy by leveraging pre-existing measles immunity. Researchers have developed a method using lipid nanoparticles (LNPs) to deliver mRNA encoding the measles virus hemagglutinin (H) protein directly into tumors. This strategy aims to redirect the body's antiviral immune response towards cancer cells, thereby enhancing the efficacy of antitumor treatments. The study highlights the potential of this approach to activate both humoral and cellular immunity, particularly through the recruitment of measles-specific CD8+ cytotoxic T lymphocytes. The research involved testing in murine and human melanoma models, showing promising results in reducing tumor growth and increasing tumor cell apoptosis. The study suggests that this method could provide a scalable and universal approach to cancer treatment by utilizing the widespread immunity to measles. 
